Exagamglogene Autotemcel for Severe Sickle Cell Disease
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) at the erythroid-specific enhancer region of BCL11A . Methods We conducted a phase 3, single-group, open-label study of exa-cel in patients 12 to 35 years of age with sickle cell disease who had had at least two severe vaso-occlusive crises in each of the 2 years before screening. CD34+ HSPCs were edited with the use of CRISPR-Cas9. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was freedom from severe vaso-occlusive crises for at least 12 consecutive months. A key secondary end point was freedom from inpatient hospitalization for severe vaso-occlusive crises for at least 12 consecutive months. The safety of exa-cel was also assessed. Results A total of 44 patients received exa-cel, and the median follow-up was 19.3 months (range, 0.8 to 48.1). Neutrophils and platelets engrafted in each patient. Of the 30 patients who had sufficient follow-up to be evaluated, 29 (97%; 95% confidence interval [CI], 83 to 100) were free from vaso-occlusive crises for at least 12 consecutive months, and all 30 (100%; 95% CI, 88 to 100) were free from hospitalizations for vaso-occlusive crises for at least 12 consecutive months (P<0.001 for both comparisons against the null hypothesis of a 50% response). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No cancers occurred. Conclusions Treatment with exa-cel eliminated vaso-occlusive crises in 97% of patients with sickle cell disease for a period of 12 months or more. (CLIMB SCD-121; ClinicalTrials.gov number, NCT03745287 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationKato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Self-citationPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Vichinsky, E., Hoppe, C. C., Ataga, K. I., Ware, R. E., Nduba, V., El-Beshlawy, A., Hassab, H., Achebe, M. M., Alkindi, S., Brown, R. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903212 · Cited by 624
Self-citationGluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., Pinto Simões, B., Ferster, A., Dupont, S., de la Fuente, J., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745711 · Cited by 495
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309673 · Cited by 253
Self-citationA trial of unrelated donor marrow transplantation for children with severe sickle cell disease
Shenoy, S., Eapen, M., Panepinto, J. A., Logan, B. R., Wu, J., Abraham, A., Brochstein, J., Chaudhury, S., Godder, K., Haight, A. E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-715870 · Cited by 216
Self-citation
Cited by
Items 201–300 of 477
Considerations for early life genetic therapies in cystic fibrosis
Cooney, A. L., Thornell, I. M., Pezzulo, A. A., Fischer, A. J., Cook, D. P., Alaiwa, M. H. A., Ode, K. L., Uç, A., Zabner, J., Ryan, A. L., et al. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00022.2026 · Cited by 2
Pavitra, E., Kumbhakar, M., Kim, B., Gupta, V. S., Gupta, P., Lee, J., Han, Y.-K., Bhaskar, L. V., Raju, G. S. R., & Huh, Y. S. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.04.003 · Cited by 2
Chetlapalli, K., Ito, S., Ng, D. Q., Sra, M. S., Wang, D., Krumholz, H. M., Krishnamurti, L., Pandya, A., & Goshua, G. (2026) · Blood · doi:10.1182/blood.2025032290 · Cited by 2
Non-genotoxic transplantation and in vivo selection through epitope editing
Casirati, G., Cosentino, A., Freschi, M., Zeng, J., Mucci, A., Levesque, S., Neri, N. R., Drago, E., Carzaniga, V., Romano, F., et al. (2026) · Nature · doi:10.1038/s41586-026-10737-8 · Cited by 6
Barve, A., Dabas, P., Cornwell, A., Sriram, P., Kopyov, O. V., Zhai, M., Kooienga, E., Kelley, Z., Johnson, J., Myers, J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adv0628 · Cited by 6
Self-citationShe, L., Liang, Z., Zou, Q., & Huo, Y. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00386 · Cited by 2
Nishigaya, Y., Takase, S., Sumiya, T., Sato, T., Niwa, H., Sato, S., Nakata, A., Matsuoka, S., Maemoto, Y., Hashimoto, N., et al. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129856 · Cited by 3
Genetic Carrier Screening — Call for a Global Mission
Henneman, L. (2024) · New England Journal of Medicine · doi:10.1056/nejme2410086 · Cited by 2
Pediatric Advances in Gene Therapies for Hemoglobinopathies
Thompson, C., Ferdjallah, A., & Gupta, A. O. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.5366 · Cited by 2
Udeze, C., Li, N., Kunzweiler, C. P., Baldwin, J. L., Tuzin, P., Zingel, S. D., Vetter, C., Dombrowski, S., Georgiadou-Schmidt, E., Alba, A., et al. (2025) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00550-2 · Cited by 4
Self-citationCollins, G. S., Levine, D. R., Leonard, A. K., Sharma, A., & Johnson, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1535851 · Cited by 2
“As it is novel therapy, less is known about outcomes following GT, however a >90% reduction in pain events after GT has been reported (17, 57, 58).”
Self-citationFrangoul, H., Locatelli, F., Eckrich, M. J., Imren, S., Li, N., Xuan, F., & Grupp, S. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03162-2 · Cited by 3
Self-citationChiong, M. A. D., & Basas, A. A. (2025) · Journal of Religion and Health · doi:10.1007/s10943-025-02318-2 · Cited by 2
“…a nonviral cell therapy exagamglogene autotemcel (exa-cel) designed to reactivate fetal hemoglobin synthesis thru ex vivo (CRISPR)- Cas9 gene editing, vaso-occlusive crises were eliminated in 97% of patients for a period of 12 months or more during a phase 3 clinical trial (Frangoul et al., 2024).”
The ASH Research Collaborative Sickle Cell Disease Research Network: past, present, and future
Rassi, F. A. E., Andemariam, B., Kutlar, A., Pace, B. S., Fink, A. K., Torres, K., Dowd, C., & Abrams, C. S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016394 · Cited by 5
Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support
Inam, Z. S., Han, H., Webb, J. L., & Delaney, M. (2025) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2025.150930 · Cited by 3
Joly, A., Schott, A., Phadke, I., González‐Menéndez, P., Kinet, S., & Taylor, N. N. (2024) · Physiology · doi:10.1152/physiol.00035.2024 · Cited by 3
Sichlinger, L., Reilly, M. B., Arora, S., Zhang, S., Marotta, N., Rodríguez-Acevedo, K. L., Hooks, M., Czarnecki, K. S., Winter, J. J., Waxman, E. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.28.685100 · Cited by 4
Die Zukunft der Medizin: ein informierter Blick in die „Glaskugel“
Grgic, I. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2410-9532 · Cited by 1
Une approche CRISPR/Cas pour traiter les β-hémoglobinopathies
Brusson, M., & Miccio, A. (2025) · médecine/sciences · doi:10.1051/medsci/2024191 · Cited by 3
Improving resolution with single-cell detection of CRISPR off-target events
Lee, C. M. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101498 · Cited by 1
Crowe, E. P., Andrews, J. C., Chou, S. T., et al. (2025) · Transfusion · doi:10.1111/trf.18330 · Cited by 1
Operating CRISPR/Cas12a in a complex nucleic acid sequence background
Hellmer, H., Mayer, T., Bauersachs, L., & Simmel, F. C. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag390 · Cited by 1
Medicine of the future: artificial intelligence, gene editing, and planetary health
Pinargote, C. A., Mero, J. G., Macias, V. D., et al. (2025) · eVitroKhem · doi:10.56294/evk2025213 · Cited by 1
El-Awaisi, J., Perrella, G., Mayor, N., Tinkova, V. V., Cleary, S. J., Grygielska, B., Watson, S. P., Dimitrov, J. D., Brill, A. G., Hassan, E., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322072 · Cited by 3
A baby benefits from personalized gene editing in the clinic
Sepp‐Lorenzino, L. (2025) · Nature · doi:10.1038/d41586-025-02590-y · Cited by 1
Perspective Chapter: Recent Developments in the Treatment of Sickle Cell Disease
Almorish, M., & Alyahawi, A. A. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1008397 · Cited by 1
How do I overcome apheresis collection challenges for sickle cell disease gene therapy
Tanhehco, Y. C., Gupta, G. K., Singh, N., Shi, P. A., Aqui, N. A., Godbey, E. A., Hofmann, J. C., Schneiderman, J., Thibodeaux, S. R., Zubair, A. C., et al. (2025) · Transfusion · doi:10.1111/trf.18461 · Cited by 1
Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy
Duesberg, M., & Schiller, G. J. (2025) · Cureus · doi:10.7759/cureus.95112 · Cited by 7
“Parallel studies, including OTQ923, have also demonstrated successful HbF reactivation and clinical benefit in early cohorts [18, 59-61].”
Lindquist, M., Stafie, S. T., Ward, C., et al. (2025) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2025.104683 · Cited by 1
Butt, H., Sathish, S., London, E., Le, A., Li, Q., Gudmundsdottir, B., Lee, D., Burke, E. V., Yates, B. P., Liu, D. R., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017321 · Cited by 4
Ramesh, B., & Fakoya, A. O. J. (2025) · Cureus · doi:10.7759/cureus.95908 · Cited by 4
“This therapy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR to edit the patient's hematopoietic stem cells, enabling them to produce fetal hemoglobin by altering the B-cell lymphoma/leukemia (BCL11A) gene [32].”
Hara, Y., Lemgart, V. T., Lessard, S., Mercadante, C. J., Ribeil, J., Hicks, A., Rimmelé, P., & Light, D. R. (2025) · Science Advances · doi:10.1126/sciadv.adx1144 · Cited by 1
Jang, Y., Eom, Y. J., Gwak, S.-H., Koh, Y., Han, J., Rim, Y. A., Nam, Y., & Ju, J. H. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04825-1 · Cited by 3
Mahlangu, J. N., Colombatti, R., James, J., Trimnell, C., Waller, J., Al-Behaisi, S., Wufsus, A. R., Morrell, G., & Andemariam, B. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00295-9 · Cited by 1
Proactive management to improve outcomes of high-risk pregnancy in people with sickle cell disease
Obadina, M. A., & Pecker, L. H. (2025) · Hematology · doi:10.1182/hematology.2025000744 · Cited by 2
Optimizing the right time to start sickle cell therapies
Martin, O. Y., & Jacob, S. A. (2025) · Hematology · doi:10.1182/hematology.2025000752 · Cited by 2
Targeting RUNX1 Germline Variants: Agents Under Investigation
Ghalamkari, S., Hahn, C. N., Lau, A., Scott, H. S., Homan, C. C., & Brown, A. L. (2025) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-025-00767-w · Cited by 1
Emerging Considerations in Transfusion Medicine
Gibson, N. M., Kwiatkowski, J. L., & Chou, S. T. (2025) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2025.10.006 · Cited by 1
Fetal Hemoglobin Research and Clinical Relevance in Sickle Cell Disease
Gudmundsdóttir, B. K., & Tisdale, J. F. (2025) · Physiology · doi:10.1152/physiol.00024.2025 · Cited by 1
HbF-inducing gene therapies for the β-hemoglobinopathies: implications for future pregnancies
Gavillet, M., Legardeur, H., Adam, C. J. M., Renella, R., Dashraath, P., & Baud, D. (2026) · Blood Red Cells & Iron · doi:10.1016/j.brci.2026.100047 · Cited by 2
Gab-Obinna, C. L., Oriaku, I., Okeoma, O. I., Olowookere, A. K., Obong, E. E., Onyedum, N. N., & Bala, J. I. (2026) · Australian Journal of Biomedical Research · doi:10.63946/aubiomed/17736 · Cited by 2
Wang, M., Zhou, T., Liu, S., Xiang, W., Xie, K., Zhang, X., Hu, W., Fang, M., Zhang, Z., Chen, M., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1715984 · Cited by 3
“This drug is also under clinical investigation for thalassemia, showing promising results with 91% of transfusion-dependent β -thalassemia patients achieving transfusion independence, although this indication has not yet been approved (Locatelli et al., 2024).”
One cell at a time: HbF distribution in sickle cell disease
Khandros, E., & Steinberg, M. H. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018293 · Cited by 1
“9,10 Proceeding with treatment using challenging therapeutics, such as allogeneic transplantation, ex vivo gene therapies that require myeloablative conditioning, or developing new HbF-inducing therapeutics, or even non-HbF–directed therapeutics, is always a fraught matter.”
Self-citationG‐ CSF for Mobilizing CD34 + Cells in Individuals With SCD : A Word of Caution
Sharma, A., Abraham, A., Bhatia, M., Cancio, M., Chaudhury, S., Corbacioglu, S., Guilcher, G. M. T., Gupta, A. O., Hanna, R., Heeney, M. M., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70235 · Cited by 1
Self-citationCurrent Status of Clinical Gene Therapy for Hemophilia and Globin Disorders
Winkler, R., Herath, I., Kaczmarek, R., Xiao, W., Herzog, R. W., & Severeid, P. (2026) · Journal of Blood Medicine · doi:10.2147/jbm.s576017 · Cited by 3
Lopez, A., Gargano, M. A., Yang, H., Ogunsile, F. J., Li, N., Xie, Y., Jeyakumar, S., & Udeze, C. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2624971 · Cited by 3
Cardiovascular Science, Medicine, and Society: The Brave New World
Regan, J. A., Laitner, M. H., & Dzau, V. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.085 · Cited by 3
Shariati, A., Homaei, A., Khezrpour, A., Azizi, N., Khani, P., Shariati, F. S., Rafiee, M., Afkhami, H., Yousefi, M. H., Saeidi, F., et al. (2026) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2026.100382 · Cited by 1
Limerick, E. M., Hsieh, M. M., Queen, J., Grecco, M. L., Varga, J., Brooks, J., Coles, W. A., Jeffries, N. O., & Fitzhugh, C. D. (2026) · PLoS ONE · doi:10.1371/journal.pone.0332282 · Cited by 1
Clinical translation of epigenome editing technologies
Ma, A. J., Brown, B. H., Kim, S., & Hilton, I. B. (2026) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2026.100666 · Cited by 3
Ten years of clinical genetic therapies for sickle cell disease: Current and future directions
Leonard, A. (2026) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.03.013 · Cited by 1
Discontinued therapies for sickle cell disease: status and future directions
Sharma, A., Suryaprakash, S., Johnson, L., & Unguru, Y. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2663116 · Cited by 1
Self-citationLife, B. E., Kazemian, P., Petkau, T. L., Gomes, A. D. M., Thomson, S. B., Shen, N., Myung, J. J. K., Jayousi, F., Lengyell, T. C., Lange, P. F., et al. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107419 · Cited by 1
Functional peptide-assisted delivery of CRISPR/Cas9: recent progress on gene editing
Cho, H. M., Ryu, Y. C., Cho, M. K., & Hwang, B. H. (2026) · Biomaterials Science · doi:10.1039/d6bm00231e · Cited by 1
Microchemical perspectives on CRISPR-based diagnostics for SARS-CoV-2 detection authors
joshi, M., Roy, A., Sahu, Y., Sahu, A., Raza, A., Pathan, I., Rathod, A. G., Dhake, P., Sharma, R., Raza, M. A., et al. (2026) · Next research. · doi:10.1016/j.nexres.2026.101849 · Cited by 1
Fourth-generation gene editors: Integration-based genome engineering
Kincaid, A. E., Hewitt, A. W., & Rajendra, K. C. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201753 · Cited by 4
Eapen, M., & Williams, D. A. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102906 · Cited by 1
Vallelian, F., Schaer, D. J., Lechartier, B., Buehler, P. W., & Irwin, D. C. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106288 · Cited by 2
High-fidelity genome and prime editing enabled by the AI-designed openCRISPR-1
Hwang, H.-Y., Yi, H., Gwon, Y., Jeon, E. J., & Kim, D. (2026) · Genome Medicine · doi:10.1186/s13073-026-01682-2 · Cited by 2
Dissecting polycomb complexes for enhanced fetal hemoglobin production
Kaminski, P. J., Min, K., Traxler, E. A., Khandros, E., Abdulmalik, O. Y., Godfrey, B. N., Keller, C. A., Giardine, B. M., Hardison, R. C., Shi, J., et al. (2026) · Blood · doi:10.1182/blood.2026033804 · Cited by 1
Ciganek, I., Delehedde, C., Galy, A. H. M., Cogné, M., Rameix, N., Bordeianu, C., & Pichon, C. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103334 · Cited by 3
“The resulting HbF compensates for defective adult hemoglobin, effectively neutralizing disease symptoms and eliminating transfusion dependence for severe sickle-cell and β -thalassemia patients [7,380].”
From blood viscosity to a hemorheology passport: Making sickle-cell monitoring clinically actionable
Vijayasimha, M., & Srikanth, M. (2026) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2026.103024 · Cited by 1
CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics
Grigg, S. E., Shembrey, C., Fareh, M., Blombery, P. A., Corn, J. E., Seymour, J. F., & Casan, J. M. L. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01179-2 · Cited by 5
Design of Nanocarriers for Kidney Targeted Delivery of Nucleic Acid Therapeutics
Lee, J. H., Han, J., Park, S., & Mok, H. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.70210 · Cited by 2
Base editing for precision therapeutics
Regmi, M., Ma, K., Bi, C., Zhang, X., Zhao, D., Yu, L., Huihui, Y., Wang, N., & Yang, C. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101298 · Cited by 2
Ruan, J., Tao, Z., Zhang, K., Wu, S., Zhou, Y., Yu, X., Zhang, H., Liu, G., & Zhang, Y. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1886383 · Cited by 1
“…frontier of disease-modifying therapy, the FDA approvals of exagamglogene autotemcel (exa-cel/Casgevy, the first CRISPR-Cas9 gene-editing therapy) (35) and lovotibeglogene autotemcel (lovo-cel/Lyfgenia) for SCD in December 2023 (36) demonstrate that curative options now exist; however, list…”
Subphenotypes of Sickle Cell Disease: A Guide to Targeting Treatment?
Steinberg, M. H. (2026) · American Journal of Hematology · doi:10.1002/ajh.70466 · Cited by 1
Self-citationAlquadan, O., Deebaja, R., Gupte, A., & Al‐Antary, E. T. (2026) · Pediatric Annals · doi:10.3928/19382359-20260629-01 · Cited by 1
Clinical base editing for β-hemoglobinopathies across different genetic backgrounds
Liu, R., Lai, Y., Wang, L., Qian, X., Ma, X.-K., Li, Y., Yang, G., Shi, L., Li, Z., Wei, J., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.08.009 · Cited by 4
Zantek, N. D., Alquist, C. R., Hofmann, J. C., Klingel, R., Levenbrown, Y., Onwuemene, O. A., Patidar, G. K., Patriquin, C. J., Raval, J. S., Sanchez, A. P., et al. (2026) · Journal of Clinical Apheresis · doi:10.1002/jca.70141 · Cited by 4
Mechanistic and Biological Perspectives on Erythropoiesis
Bresnick, E. H., Papayannopoulou, T., & Migliaccio, A. R. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104286 · Cited by 1
Exagamglogene autotemcel: a beacon of hope for severe sickle cell disease and thalassemia management
Anand, A., Singh, M. P., Sharma, R. K., Khatib, M. N., Gaidhane, S., Zahiruddin, Q. S., Rustagi, S., & Melese, E. B. (2024) · International Journal of Surgery Open · doi:10.1097/io9.0000000000000146 · Cited by 1
Gowen, B. G., Khekare, P., McCawley, S., et al. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0053 · Cited by 1
On the cutting edge of sickle cell disease: a snapshot narrative review
Menshawey, R., & Menshawey, E. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00573-8 · Cited by 1
Baldwin, J. L., Udeze, C., Li, N., Boulmerka, L., Dahal, L., Pesce, G., Quignot, N., Jiang, H., & Galactéros, F. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2421287 · Cited by 1
Mormin, M., Rigonnot, L., Chalumeau, A., Miccio, A., Fournier, C., Pajanissamy, S., Dewannieux, M., & Galy, A. H. M. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.098 · Cited by 1
Should we use bisphosphonates to treat bone complications in sickle cell disease?
Gollamudi, J., & Adesina, O. (2024) · Hematology · doi:10.1182/hematology.2024000671 · Cited by 1
Shrestha, A., Pillis, D. M., Felker, S., Chi, M., Wagner, K., Gbotosho, O. T., Sieling, J., Shadid, M., & Malik, P. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101439 · Cited by 1
Emerging need for a hepato-hematology program for patients with sickle cell disease in Saudi Arabia
Al-Judaibi, B., Alzahrani, H. A., Alahmari, A. D., et al. (2025) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_419_24 · Cited by 1
“[31,32] The two approved products, exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) are cell‑based gene therapies that start with gene modifying the collected CD34 cells, followed by myeloablative conditioning and then infusion of the CD34 cells.”
Who will pay for these miraculous new medical therapies?
Guenot, M. (2025) · BMJ · doi:10.1136/bmj.r286 · Cited by 1
Preclinical therapeutics for sickle cell disease: modern developments and future considerations
Okpala, I. E., Nonyelu, C. E., Muoghalu, E., Anigbogu, I. O., Onodugo, C., Ilechukwu, G. U., Fidelis-Ewa, U., Duru, A. N., & Okoye, H. C. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2500289 · Cited by 3
El-Awaisi, J., Perrella, G., Mayor, N., Tinkova, V. V., Cleary, S. J., Grygielska, B., Watson, S. P., Dimitrov, J. D., Brill, A. G., Nicolson, P. L. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.04.592537 · Cited by 1
Lorenzini, M. H., Balderson, B., Lavalle, S. N., Sajeev, K., Ho, A. J., Light, M., Usman, O. H., Kurgan, G., & McVicker, G. (2026) · Nature Methods · doi:10.1101/2025.02.07.636966 · Cited by 4
Moum, S. J., Barry, M., Scoville, J., Bishop, C. K., Lam, S. K., & Shaibani, A. (2025) · Neurographics · doi:10.3174/ng.2400078 · Cited by 1
Gomez‐Ospina, N., Vera, L. P., Gastou, M., Colella, P., Basurto, J. A., Feng, A., Lin, Y., Zhao, X., & Sun, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7123212/v1 · Cited by 1
GENETH’OFF: a flexible workflow for genome-wide profiling of CRISPR/Cas off-targetsPreprint
Corre, G., Rouillon, M., Mombled, M., & Mario, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.30.679427 · Cited by 2
Brain-wide Genome Editing via STEP-RNPs for Treatment of Angelman SyndromePreprint
Lu, X., Xie, Y., Bao, Y., Yu, J., Wang, Z., Fan, J., Sheu, W. C., Long, G., Tu, Z., Tong, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.13.684643 · Cited by 1
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasmsPreprint
Doll, R. M., Shen, Y., Wong, Z. C., Slama, R., Greco, M. T., Cheng, L., Louka, E., Zhang, W., Bozhilov, Y. K., Hamley, J. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.17.694595 · Cited by 1
Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cellsPreprint
Yu, M., Das, P., Horton, J. R., Zhou, J., Lee, J. J., Hong, T., Lu, Y., Estecio, M. R., Iakova, P. A., Jain, A. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.06.704516 · Cited by 1
Brennan, M. T., Passineau, M. J., Saunders, D., Sroussi, H., Gaudilliere, D., Liu, J., Dubois, N., Fernandez, A., & Zeldin, R. K. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.04.002 · Cited by 1
Ventura, A. (2024) · Medico e Bambino · doi:10.53126/meb43349
Fibrillarin modulates fetal hemoglobin silencingPreprint
Wu, D., Li, Q., Qiu, S., Guo, C., Li, F., Shangguan, W., Li, W., Yang, D., Meng, X., Xing, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.25.600532
Studies of Exagamglogene Autotemcel — Age and Place
Frangoul, H., Hobbs, W. E., & Locatelli, F. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2407381
Self-citation… und schon wieder eine neue Ära?
Schrezenmeier, H. (2024) · Transfusionsmedizin · doi:10.1055/a-2138-6451
Gene Therapy Should Be the Cell Therapy of Choice for Sickle Cell Disease
Boelens, J. J. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(24)00377-x
Delafoy, M., Dalle, J., Pondarré, C., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27486
Classical Haematology: Dynamic Development at the Interface of Transfusion Medicine and Haematology
Schrezenmeier, H. (2024) · Transfusion Medicine and Hemotherapy · doi:10.1159/000540110
Mahesri, M., Lee, S. B., Levin, R., Imren, S., Zhang, L., Beukelman, T., Titievsky, L., & Desai, R. J. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3449
Self-citationRevisiting γ-globin gene repression by TR4
Perkins, A. C. (2024) · Blood · doi:10.1182/blood.2024026481
Besondere hereditäre Erkrankungen bei Patient*innen mit Migrationshintergrund
Kauerz, H.-M. (2025) · Notaufnahme up2date · doi:10.1055/a-2305-9007
Metadata
- Authors
- Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., Cavazzana, M., Corbacioglu, S., Rondelli, D., Meisel, R., Dedeken, L., Lobitz, S., de Montalembert, M., Steinberg, M. H., Walters, M. C., Eckrich, M. J., Imren, S., Bower, L., Simard, C., Zhou, W., Xuan, F., Morrow, P. K., Hobbs, W. E., & Grupp, S. A.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Sarah Cannon Research Institute at the Children’s Hospital at TriStar Centennial (H.F.), Nashville, and Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis (A.S.) — both in Tennessee; IRCCS, Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome (F.L.); the Department of Pediatrics, Columbia University Irving Medical Center, New York–Presbyterian–Morgan Stanley Children’s Hospital (M.B.), and the Department of Medicine, Division of Hematology–Oncology, Columbia University (M. Mapara) — both in New York; Sarah Cannon Pediatric Transplant and Cellular Therapy Program at Methodist Children’s Hospital, San Antonio, TX (L.M., M.J.E.); the Hospital for Sick Children and the University of Toronto, Toronto (D.W.); Ann and Robert H. Lurie Children’s Hospital of Chicago (R.I.L.) and the University of Illinois at Chicago (D.R.) — both in Chicago; Royal London Hospital, Barts Health NHS Trust, London (P.T.); Stanford University, Palo Alto (A.J....
- ORCID
- Frangoul, Haydar
- Locatelli, Franco
- Sharma, Akshay
- Bhatia, Monica
- Mapara, Markus
- Wall, Donna
- Liem, Robert I.
- Telfer, Paul
- Shah, Ami J.
- Cavazzana, Marina
- Corbacioglu, Selim
- Rondelli, Damiano
- Meisel, Roland
- Dedeken, Laurence
- Lobitz, Stephan
- Steinberg, Martin H.
- Walters, Mark C.
- Eckrich, Michael J.
- Imren, Suzan
- Zhou, Weiyu
- Xuan, Fengjuan
- Morrow, Phuong Khanh
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1649-1662
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068280
- Cited by
- 493
- References
- 29
- Citations by year
- 2026: 217 · 2025: 201 · 2024: 74
- FWCI
- 137.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Vertex Pharmaceuticals
- CRISPR Therapeutics
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, sickle cell disease, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin reactivation, hematopoietic stem and progenitor cells, vaso-occlusive crisis, myeloablative conditioning, busulfan, autologous cell transplantation, cell therapy safety, pediatric patients
- MeSH terms
- Gene Editing, Adolescent, Adult, Anemia, Sickle Cell, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.